Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report published on Monday,Benzinga reports. Guggenheim currently has a $125.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Barclays raised their price objective on shares of Oruka Therapeutics from $50.00 to $78.00 and gave the company an “overweight” rating in a research note on Tuesday, April 7th. Leerink Partners raised their price objective on shares of Oruka Therapeutics from $58.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. BTIG Research raised their price objective on shares of Oruka Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a research note on Monday. Stifel Nicolaus raised their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Piper Sandler began coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 price objective on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.90.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $65.55 on Monday. Oruka Therapeutics has a 12 month low of $8.31 and a 12 month high of $67.94. The firm has a market capitalization of $3.25 billion, a PE ratio of -35.24 and a beta of -0.54. The company’s 50 day simple moving average is $41.37 and its 200 day simple moving average is $33.23.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. Sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00. Following the sale, the insider owned 33,377 shares of the company’s stock, valued at $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,765 shares of company stock valued at $1,089,745 over the last 90 days. 24.69% of the stock is currently owned by insiders.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in ORKA. Viking Global Investors LP bought a new stake in Oruka Therapeutics during the third quarter worth approximately $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in Oruka Therapeutics during the fourth quarter worth approximately $51,840,000. Remedium Capital Partners LLC bought a new stake in Oruka Therapeutics during the fourth quarter worth approximately $47,054,000. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics during the third quarter worth approximately $25,640,000. Finally, Deep Track Capital LP boosted its holdings in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $85 and assigned an “outperform” rating, a notable bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
• Positive Sentiment: BTIG boosted its price target to $78, adding further analyst-driven momentum that may support buying interest. BTIG raises ORKA target to $78
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $70 target while publishing multi?quarter and FY2026–FY2027 EPS forecasts (FY2027: -$3.55), signaling continued analyst conviction despite losses; this sustained buy-side research supports the stock’s rally. HC Wainwright coverage
• Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre?arranged Rule 10b5?1 plan, reducing her stake ~17.3%; because the sale was pre?planned and disclosed via SEC Form 4, it’s less likely to signal new negative information, but it can still be perceived as supply pressure. SEC Form 4
• Negative Sentiment: Consensus and firm forecasts confirm continued multi?year losses (consensus FY current year ~ -$3.41 EPS; HC Wainwright FY2027 -$3.55), which keeps valuation reliant on future clinical/ commercial successes and may cap multiple expansion despite high price?target activity.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.